Cambridge-based Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, has announced a global strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have […]

Cambridge-based GO Therapeutics, a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, announced in early October that it has entered into a license agreement with Roche. The agreement grants Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target. Under the terms of the agreement, Roche will pay […]

Boston-based Paratek Pharmaceuticals has announced that the FDA has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug […]

Alexion, newly headquartered in Boston’s Seaport District after its move from New Haven, announced in late September that it is acquiring Syntimmune, a clinical-stage biotech developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). Syntimmune’s SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes […]

Bedford-based Stoke Therapeutics has announced it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. Stoke, which launched in 2018 with a $40 million Series A investment, has identified thousands of genes that could be addressed by its proprietary TANGO […]

Enterome, a clinical-stage French biotech with its U.S. headquarters in Cambridge, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical. Enterome is developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer. The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, […]

Bain Capital and Pfizer have announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS) to be headquartered in the greater Boston area. Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical-stage compounds and several […]

[The following post has been excerpted from “For Journalists: Statement and Background on the CRISPR Patent Decision” by Lee McGuire, Chief Communications Officer, Broad Institute of MIT and Harvard.] A federal panel has again confirmed that the patents granted by USPTO to the Broad Institute, MIT and Harvard concerning CRISPR editing of eukaryotic genomes do […]

Alnylam Pharmaceuticals has announced the European Commission (EC) has granted marketing authorization for Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. The approval was granted less than three weeks after Alnylam won FDA approval for Onpattro. The drug is based on Nobel Prize-winning science […]